Genetics Institute, Inc.

Leslie D Lowe

Mary Collins

Glenn R Larsen

Debra D Donaldson

Matthew James Whitters

Beatriz M Carreno

Deborah A Young

Laura L Carter

Michelle J Unger

Marion T Kasaian

Joann Witek

Kyri Dunussi

Margery Ma

Joann S Witek

Michelle Ungar

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ('IL-21R' or 'MU-1'), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

Methods and compositions for modulating interleukin-21 receptor activity

Growing community of inventors

Sudbury, MA, United States of America

Leslie D Lowe